Stock Analiz

Boston Scientific Corp. (BSX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Boston Scientific’s revenue went from $9.1B in fiscal 2016 to $20.1B in fiscal 2025, growth of about 9.2% a year.

Net income in fiscal 2025 was $2.9B, a net margin of 14.4%; the best year in this period was 2019 with $4.7B.

Over the twelve months to September 30, 2026, revenue was $21.1B and net income $3.5B.

Free cash flow was $3.7B in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count rose 9% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $9.1B162017: $9.0B172018: $9.8B182019: $10.7B192020: $9.9B202021: $11.9B212022: $12.7B222023: $14.2B232024: $16.7B242025: $20.1B25$20.1B
Net income
2016: $347M162017: $104M172018: $1.7B182019: $4.7B192020: -$115M202021: $985M212022: $642M222023: $1.6B232024: $1.9B242025: $2.9B25$2.9B
Free cash flow
2016: $806M162017: $1.1B172018: -$6M182019: $1.4B192020: $1.1B202021: $1.3B212022: $938M222023: $1.8B232024: $2.6B242025: $3.7B25$3.7B
EPS (diluted)
2016: $0.25162017: $0.08172018: $1.19182019: $3.33192020: $-0.08202021: $0.69212022: $0.45222023: $1.07232024: $1.25242025: $1.9425$1.94

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$21.1B$20.1B$16.7B$14.2B$12.7B$11.9B$9.9B$10.7B$9.8B$9.0B$9.1B
Gross profit$14.6B$13.9B$11.5B$9.9B$8.7B$8.2B$6.4B$7.6B$7.0B$6.5B$6.0B
Operating income$3.9B$3.6B$2.6B$2.3B$1.6B$1.2B-$80M$1.5B$1.5B$1.3B$447M
Net income$3.5B$2.9B$1.9B$1.6B$642M$985M-$115M$4.7B$1.7B$104M$347M
EPS (diluted)$2.36$1.94$1.25$1.07$0.45$0.69$-0.08$3.33$1.19$0.08$0.25
R&D$2.2B$2.1B$1.6B$1.4B$1.3B$1.2B$1.1B$1.2B$1.1B$997M$920M
Revenue growth—+19.9%+17.6%+12.3%+6.7%+19.9%−7.7%+9.3%+8.6%−0.3%+12.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$4.2B$4.5B$3.4B$2.5B$1.5B$1.9B$1.5B$1.8B$310M$1.4B$1.2B
Capital spending-$903M-$876M-$790M-$711M-$588M-$554M-$376M-$461M-$316M-$319M-$376M
Free cash flow$3.3B$3.7B$2.6B$1.8B$938M$1.3B$1.1B$1.4B-$6M$1.1B$806M
Dividends paid——$0$28M$55M$55M$28M$0$0——
Buybacks————$0$0$535M$0$0—$0
Stock-based pay$313M$299M$266M$233M$220M$194M$170M$157M$140M$127M$116M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$2.0B$414M$865M$928M$1.9B$1.7B$217M$146M$188M$196M
Debt—$12.0B$11.2B$9.6B$9.3B$9.5B$9.5B$10.4B$7.1B$5.6B$5.7B
Equity—$24.2B$21.8B$19.3B$17.6B$16.6B$15.3B$13.9B$8.7B$7.0B$6.7B
Total assets—$43.7B$39.4B$35.1B$32.5B$32.2B$30.8B$30.6B$21.0B$19.0B$18.1B
Shares (diluted)1.45B1.49B1.49B1.46B1.44B1.43B1.42B1.41B1.40B1.39B1.38B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin69.1%69.0%68.6%69.5%68.8%68.8%65.0%71.0%71.4%71.3%65.7%
Operating margin18.7%18.0%15.5%16.4%13.0%10.1%-0.8%14.1%15.3%14.2%4.9%
Net margin16.6%14.4%11.1%11.0%5.1%8.3%-1.2%43.8%17.0%1.1%3.8%
FCF margin15.8%18.2%15.8%12.6%7.4%11.1%11.4%12.8%-0.1%12.2%8.9%
ROIC—8.5%6.4%6.5%3.8%4.4%-0.2%5.0%7.5%8.0%2.9%
ROE—12.0%8.5%8.1%3.6%5.9%-0.8%33.9%19.1%1.5%5.1%

Frequently asked questions

What is Boston Scientific’s annual revenue?

$20.1B in fiscal 2025 and $21.1B over the twelve months to September 30, 2026.

How much profit does Boston Scientific make?

Net income was $2.9B in fiscal 2025 (net margin 14.4%).

Is Boston Scientific’s revenue growing?

Yes: revenue rose 19.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.